On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

In recent months Novo Nordisk has invested several billions of dollars to boost its manufacturing capacity—including its ...

In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk's Lotte Bjerre Knudsen says her determination is a key part of the success, but she also stays humble.

In a report released today, Peter Welford from Jefferies maintained a Sell rating on Novo Nordisk (0QIU – Research Report). The company’s ...

Denmarks economic prospects are surging, with the government revising GDP growth forecasts upwards for 2024 and 2025, largely ...

Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to ...

A Scandinavian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of ...

A dOZEN YEARS ago Spain was a byword for economic failure. The country’s government and banks appeared to be locked in a ...

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

The Harbor Diversified International All-Cap Fund performed broadly in line with its benchmark, the MSCI All Country World Ex ...